Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Drug Safety Reforms Not Enough To Fix Problems, IoM Committee Says

Executive Summary

A separate postmarketing safety center may become necessary if the recommendations made by the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System do not result in sufficient reforms of FDA's safety oversight, the committee says

You may also be interested in...



Rx Safety: FDA Needs Deadline - Not Funding - To Improve Process, GAO Says

GAO is not buying an FDA assertion that the delay in giving the Office of Surveillance and Epidemiology more responsibility for post-market drug safety decisions is a funding issue

Rx Safety: FDA Needs Deadline - Not Funding - To Improve Process, GAO Says

GAO is not buying an FDA assertion that the delay in giving the Office of Surveillance and Epidemiology more responsibility for post-market drug safety decisions is a funding issue

FDA’s Sentinel Program Readies For Patrol As Stakeholders Watch For Details

HHS unveiled the first phase of FDA's "Sentinel" post-market drug safety surveillance initiative with fanfare May 22, but stakeholders will have to wait a while for details on funding and the timing of a full-scale rollout

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS047617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel